{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.opnabio.com/#organization",
      "name": "Opna Bio",
      "legalName": "Opna Bio, Inc.",
      "url": "https://www.opnabio.com/",
      "description": "Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s lead program is OPN-6602, a dual EP300/CBP inhibitor, currently in a Phase 1 clinical trial in patients with multiple myeloma."
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/opna-bio#asg",
      "name": "Opna Bio ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/opna-bio",
      "isPartOf": {
        "@id": "https://www.opnabio.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}